|
|
 |
|
Viewing report
|
|
|
|
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
Decision Resources, Inc., Sep 2009, Pages: 24
Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as creating more entrepreneurial environments modeled upon biotech companies—increase their productivity?
Many major companies are reorganizing the research branches of their businesses and finding creative ways to partner with biotech companies and with each other to access or acquire promising technologies and pipelines. Their goal is to reinvigorate R&D and combat the effects of patent expirations, generics competition, and other industry pressures.
Questions Answered in This Report
In recent years, drug developers have invested heavily in various R&D technologies.
- Is this investment increasing R&D productivity?
- What technology strategies are most promising?
- What new approaches are pharmaceutical companies using to access enabling technologies for drug discovery?
Pharmaceutical companies are seeking to reinvigorate R&D organizations to improve productivity.
- What steps are leading companies taking to change R&D?
- What structures and strategies have already been implemented within Big Pharma R&D organizations?
- Can pharmaceutical companies replicate the innovation of biotech companies by reforming R&D?
Biotech companies are an important source of novel technologies and drug candidates.
- How do acquisitions of and collaborations with biotech companies fit into Big Pharma’s R&D strategies?
- How can companies use business development activities to build up technological capabilities and pipelines?
Several Big Pharma companies are charting new territory in early-stage pharma-pharma dealmaking.
- Which companies have recently formed innovative partnerships that include early-stage development?
- What are the key features of these arrangements?
- How do these ventures meet the strategic needs of both partners?
Scope
- Technology strategies: Use of high-throughput technologies and R&D productivity, biologics platforms, pharma-pharma ventures for enabling technology development.
- Organizational structures and strategies: Restructuring R&D, emulating biotech, case studies of R&D reorganization.
- Building R&D through business development: M&As, collaborations, R&D strategies.
- Pharma-pharma partnering: Strategic alliances among Big Pharma companies, Phase I co development collaboration, therapeutic area joint venture.
- Outsourcing R&D: China, India, potential advantages and disadvantages.
- Outlook for pharmaceutical R&D: Changing business models, personalized medicine, pursuing novel targets, collaboration, high-throughput strategies, translational medicine.
Customers who bought this item also bought
New Approaches to Pharma R&D: Evolving Strategies to Rejuvenate R&D Efficiency
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Bio/Pharma R&D Statistical Sourcebook 2008/2009
Innovative Strategies and Models for R&D Success: The Evolving Networked Pharma Company
Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI
Strategic Alliances in World Pharma and Biotech Markets
Innovative Drug R&D in China
Pharmaceutical R&D Statistical Sourcebook 2005/2006
R&D Strategies: Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines
China’s Attraction and Strategies to Work with It: Analysis of Best Strategies for Western Pharmaceutical and Biotech Companies to Partner with Chinese Pharmaceutical Companies
|
|
|
|
